Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Patients who have pre-existing moderate or worse NPDR at baseline need to be seen more frequently to monitor for EWDR
Individuals who carried on receiving the semaglutide had their risk scores decrease by a further 7.7%, while the risk score increased by 15.4% in those who were switched to the placebo
These are not surrogate endpoints
This article outlines what participants can expect regarding dosing, side effects, appetite and weight changes, safety considerations, and the monitoring involved in trial settings
doi: 10.3389/fcimb.2021.627608 15
US$ 26.16
US$ 28.88
US$ 23.76
US$ 26.70
US$ 20.80
US$ 26.20
US$ 29.46
